Section Arrow
LBRX.NASDAQ
- LB Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/10/19 01:14 EDT
Regular Hours
Last
 36.74
+0.05 (+0.14%)
Day High 
37.37 
Prev. Close
36.69 
1-M High
43.94 
Volume 
724.81K 
Bid
31.11
Ask
36.8
Day Low
36.06 
Open
36.62 
1-M Low
33.13 
Market Cap 
1.18B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 35.33 
20-SMA 37.33 
50-SMA 43.04 
52-W High 50.16 
52-W Low 14.3166 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.10/-5.95
Enterprise Value
1.19B
Balance Sheet
Book Value Per Share
10.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatmentof neuropsychiatric diseases, including schizophrenia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.